What are the recommended dosing, monitoring, and contraindications for romiplostim (Nplate) in adults with chronic immune thrombocytopenia refractory to corticosteroids, immunoglobulins, or other standard therapies?

Romiplostim (Nplate) for Chronic Immune Thrombocytopenia

Indications and Patient Selection

Romiplostim is indicated for adults with chronic ITP who have had insufficient response to corticosteroids, immunoglobulins, or splenectomy, and for pediatric patients ≥1 year old with ITP lasting ≥6 months who have failed these therapies. 1

• The American Society of Hematology (ASH) 2019 guidelines suggest using a TPO-RA (either romiplostim or eltrombopag) rather than rituximab for adults with ITP ≥3 months who are corticosteroid-dependent or unresponsive 2
• Either splenectomy or a TPO-RA are acceptable options, with the choice based on patient preference regarding surgery versus long-term medication 2
• Romiplostim should only be used when thrombocytopenia increases bleeding risk—not to normalize platelet counts 1

Dosing Protocol

Initial Dosing

Start romiplostim at 1 mcg/kg subcutaneously once weekly, using actual body weight at treatment initiation. 1

• Administer only with syringes containing 0.01 mL graduations due to potentially small volumes 1
• Most adult responders in clinical trials achieved target platelets with median doses of 2-3 mcg/kg 1
• Pediatric patients in controlled trials required higher median doses (5.5 mcg/kg during weeks 17-24) 1

Dose Adjustments

Adjust weekly dose by 1 mcg/kg increments based on platelet response, with maximum weekly dose of 10 mcg/kg: 1

• If platelets <50 × 10⁹/L: Increase dose by 1 mcg/kg
• If platelets 200-400 × 10⁹/L for 2 consecutive weeks: Reduce dose by 1 mcg/kg
• If platelets >400 × 10⁹/L: Withhold dose, monitor weekly, resume at reduced dose (minus 1 mcg/kg) when platelets fall below 200 × 10⁹/L 1

Important caveat: Some patients experience precipitous platelet declines when dosing is withheld per FDA recommendations at counts >400 × 10⁹/L. In these cases, continuous weekly dosing with twice-weekly monitoring may prevent severe fluctuations 3

Pediatric-Specific Considerations

• Reassess body weight every 12 weeks for dose recalculation 1
• Future dose adjustments account for both platelet changes AND weight changes 1

Monitoring Requirements

During Dose Adjustment Phase

Obtain complete blood counts with platelet counts weekly until stable dose established. 1

After Dose Stabilization

Monitor CBC with platelets monthly once stable dose achieved. 1

After Discontinuation

Monitor CBC with platelets weekly for at least 2 weeks following romiplostim cessation to detect rebound thrombocytopenia 1

Treatment Duration and Discontinuation

Discontinue romiplostim if platelet count does not increase sufficiently to avoid clinically important bleeding after 4 weeks at maximum dose (10 mcg/kg). 1

• Clinical trial data demonstrate sustained responses for up to 156 weeks (median 69 weeks) 4
• Patients with newly diagnosed ITP initiating romiplostim showed higher durable platelet response (64.6%) compared to those with chronic disease (52.7%) 5
• After treatment cessation, newly diagnosed patients maintained higher median platelet counts (138 × 10⁹/L) versus chronic patients (71 × 10⁹/L) 5

Contraindications and Precautions

Absolute Contraindications

Romiplostim is contraindicated for thrombocytopenia due to myelodysplastic syndrome (MDS) or causes other than ITP due to increased risk of progression to acute myeloid leukemia 1

Key Safety Concerns

• Thrombotic/thromboembolic complications: Monitor for signs/symptoms, particularly in patients with known risk factors 1
• Bone marrow reticulin formation: Peripheral blood smear abnormalities may indicate need for bone marrow examination 1
• Rebound thrombocytopenia: Occurs after discontinuation, requiring close monitoring 1

Clinical Efficacy Data

Romiplostim demonstrates superior efficacy compared to standard care, with 2.3 times higher platelet response rate (95% CI: 2.0-2.6, P<0.001). 6

• Treatment failure occurred in only 11% with romiplostim versus 30% with standard care (P<0.001) 6
• Splenectomy rates reduced from 36% to 9% (P<0.001) 6
• Lower bleeding event rates, fewer transfusions, and improved quality of life versus standard care 6
• Overall platelet response (durable plus transient) achieved in 83% of patients 4

Alternative Dosing Strategies

Emerging evidence suggests higher initial doses (≥2 mcg/kg) may accelerate platelet response in hospitalized, treatment-refractory patients. 7, 8

• Patients receiving initial doses ≥2 mcg/kg (median 4.5 mcg/kg) achieved platelets ≥10 × 10⁹/L in median 2 days versus 4.5 days with standard 1 mcg/kg dosing 8
• Higher initial dosing associated with shorter hospital length of stay (13.5 vs 20 days) 8
• Real-world practice at academic centers shows median initial doses of 3.8 mcg/kg, with 51% achieving target platelets by week 1 7
• This approach remains off-label and requires further prospective validation 7, 8

Choice Between TPO-RAs

ASH guidelines suggest either eltrombopag or romiplostim for adults with ITP ≥3 months who are corticosteroid-dependent or unresponsive, with choice based on patient preference for daily oral medication versus weekly subcutaneous injection. 2